+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Colistin exposure as a risk factor for infections caused by inherently colistin resistant Enterobacteriaceae-a case-control study

Colistin exposure as a risk factor for infections caused by inherently colistin resistant Enterobacteriaceae-a case-control study

Clinical Microbiology and Infection 24(8): 896-899

Epidemiological studies have suggested an association between increased colistin use and selection for inherently colistin-resistant Enterobacteriaceae (ICRE). We aimed to evaluate whether colistin exposure is a risk factor for ICRE infection. A matched 1:1 case-control study including patients recently hospitalized for ≥14 days with ICRE infection as cases matched with similar patients with a clinical isolate of a colistin-susceptible Enterobacteriaceae as controls was performed. Univariate analysis using McNemar test and multivariate analysis were conducted to explore risk factors for ICRE isolation, including colistin exposure 90 days before the positive culture. We included 446 patients, 223 cases and 223 controls matched for gender, age, department, year, source of culture and duration of hospitalization before positive culture. Colistin exposure was significantly associated with ICRE isolation in both univariate (14/223, 6.3% of cases versus 4/223, 1.8% of controls, p 0.031) and multivariate analyses (odds ratio 4.415, 95% CI 1.078-18.082). Curtailed functional capacity was a significant risk factor for ICRE as well. Exposure to other broad-spectrum antibiotics was associated with isolation of a colistin-susceptible pathogen. Exposure to colistin is associated with an increased risk of isolating an inherently colistin-resistant Enterobacteriaceae in patients with prolonged hospitalization. This should be taken into account while considering empirical therapy for such patients. Use of colistin should be judicious. The correlation between duration and magnitude of exposure and ICRE infection should be investigated in further studies.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055277397

Download citation: RISBibTeXText

PMID: 29217278

DOI: 10.1016/j.cmi.2017.11.022

Related references

Risk factors for colistin-resistant Enterobacteriaceae in a low-endemicity setting for carbapenem resistance - a matched case-control study. Euro Surveillance 23(30), 2018

Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. Bmj Open 6(4): E009956, 2017

Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. European Journal of Clinical Microbiology and Infectious Diseases 33(8): 1311-1322, 2015

Colistin Monotherapy Versus Colistin and Rifampin Combination Therapy in Pneumonia Caused by Colistin-resistant Acinetobacter baumannii: A Randomized Controlled Trial. Journal of Global Antimicrobial Resistance 2018, 2018

National survey of colistin resistance among carbapenemase-producing Enterobacteriaceae and outbreak caused by colistin-resistant OXA-48-producing Klebsiella pneumoniae, France, 2014. Euro Surveillance 21(37), 2017

Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clinical Microbiology and Infection 12(5): 497-498, 2006

Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clinical Microbiology and Infection 21(12): 1106.E1-8, 2016

Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure. Clinical Microbiology and Infection 21(8): 758-764, 2016

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet. Infectious Diseases 18(4): 391-400, 2018

Independent emergence of colistin-resistant Enterobacteriaceae clinical isolates without colistin treatment. Journal of Clinical Microbiology 49(11): 4022-4023, 2012

Ursolic acid inhibits colistin efflux and curtails colistin resistant Enterobacteriaceae. Amb Express 9(1): 27, 2019

Trends of isolation of intrinsically resistant to colistin Enterobacteriaceae and association with colistin use in a tertiary hospital. European Journal of Clinical Microbiology and Infectious Diseases 33(9): 1505-1510, 2015

Efficacy and safety of colistin for the treatment of infections caused by multidrug-resistant isolates of Pseudomonas aeruginosa sensitive to colistin in patients with haematological malignancy; a matched-pair analysis. 2007

Synergistic effect of colistin combined with PFK-158 against colistin-resistant Enterobacteriaceae. Antimicrobial Agents and ChemoTherapy 2019, 2019

Synergistic Activity of Colistin-Containing Combinations against Colistin-Resistant Enterobacteriaceae. Antimicrobial Agents and ChemoTherapy 62(10), 2018